Drug Application

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.